This advisory highlights more than 100 poster abstracts that will be presented at ASH 2025 involving researchers ...

Immix Biopharma, Inc. is building strength in its pipeline with impressive early signals in AL amyloidosis. Learn more about ...

Doctors closely monitor myeloma. The tests you have and how often you have them depend on your situation. You might have regular appointments and tests to: monitor myeloma without symptoms ...

The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.

HDP-101, an ADC, received FDA fast track designation for multiple myeloma, highlighting its potential in addressing unmet medical needs. Phase 1/2a trials show HDP-101's promising efficacy and ...

A patient with a chronic, large fibre sensory neuropathy had an immunoglobulin M lambda monoclonal paraprotein reactive at titres in excess of 1/10(5) with NeuNAc(alpha 2-8)NeuNAc(alpha 2-3)Gal ...

Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the third quarter ended September 30, 2025 and ...

- Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 - - Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $32.0 Million, an increase ...

What is the aim of treatment? The main aim of your treatment is to try to get the myeloma under control. Myeloma is not usually curable but treatment can control it. When there's no sign of active ...

Neurologists, neurology residents and fellows, medical students, social workers, masters in administration, physician assistants, nurse practitioners, nurses and pharmacists. Additionally, Neurology ...